Fortress Biotech annual operating margin
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Fortress Biotech's operating margin was −114.67% for fiscal 2025.
View full Fortress Biotech company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −114.67% | +85.53 pp |
| 2024 | 2024-12-31 | −200.20% | +38.38 pp |
| 2023 | 2023-12-31 | −238.58% | +48.15 pp |
| 2022 | 2022-12-31 | −286.73% | +11.91 pp |
| 2021 | 2021-12-31 | −298.64% | −86.94 pp |
| 2020 | 2020-12-31 | −211.70% | +105.65 pp |
| 2019 | 2019-12-31 | −317.34% | +195.99 pp |
| 2018 | 2018-12-31 | −513.33% | +65.25 pp |
| 2017 | 2017-12-31 | −578.58% | −179.86 pp |
| 2016 | 2016-12-31 | −398.73% | +5456.55 pp |
| 2015 | 2015-12-31 | −5,855.27% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −56.09% | +186.92 pp |
| Q1 2026 | 2026-03-31 | −48.61% | +121.24 pp |
| Q4 2025 | 2025-12-31 | −28.76% | +160.86 pp |
| Q3 2025 | 2025-09-30 | −40.01% | +111.03 pp |
| Q2 2025 | 2025-06-30 | −243.01% | −55.95 pp |
| Q1 2025 | 2025-03-31 | −169.85% | +110.78 pp |
| Q4 2024 | 2024-12-31 | −189.62% | −61.08 pp |
| Q3 2024 | 2024-09-30 | −151.04% | −60.99 pp |
| Q2 2024 | 2024-06-30 | −187.06% | +108.35 pp |
| Q1 2024 | 2024-03-31 | −280.63% | +203.28 pp |
| Q4 2023 | 2023-12-31 | −128.54% | +214.61 pp |
| Q3 2023 | 2023-09-30 | −90.05% | +226.19 pp |
| Q2 2023 | 2023-06-30 | −295.41% | −16.14 pp |
| Q1 2023 | 2023-03-31 | −483.90% | −256.60 pp |
| Q4 2022 | 2022-12-31 | −343.16% | +32.16 pp |
| Q3 2022 | 2022-09-30 | −316.24% | −61.66 pp |
| Q2 2022 | 2022-06-30 | −279.28% | +1.05 pp |
| Q1 2022 | 2022-03-31 | −227.30% | +52.73 pp |
| Q4 2021 | 2021-12-31 | −375.32% | −198.22 pp |
| Q3 2021 | 2021-09-30 | −254.58% | −10.66 pp |
| Q2 2021 | 2021-06-30 | −280.33% | −10.59 pp |
| Q1 2021 | 2021-03-31 | −280.04% | −99.82 pp |
| Q4 2020 | 2020-12-31 | −177.10% | +96.48 pp |
| Q3 2020 | 2020-09-30 | −243.92% | −6.46 pp |
| Q2 2020 | 2020-06-30 | −269.74% | +38.71 pp |
| Q1 2020 | 2020-03-31 | −180.21% | +352.16 pp |
| Q4 2019 | 2019-12-31 | −273.58% | +262.56 pp |
| Q3 2019 | 2019-09-30 | −237.46% | +308.30 pp |
| Q2 2019 | 2019-06-30 | −308.45% | +71.25 pp |
| Q1 2019 | 2019-03-31 | −532.38% | +87.92 pp |
| Q4 2018 | 2018-12-31 | −536.14% | −466.60 pp |
| Q3 2018 | 2018-09-30 | −545.76% | −500.01 pp |
| Q2 2018 | 2018-06-30 | −379.70% | −340.36 pp |
| Q1 2018 | 2018-03-31 | −620.29% | −467.80 pp |
| Q3 2017 | 2017-09-30 | −69.54% | +1596.72 pp |
| Q2 2017 | 2017-06-30 | −45.75% | +633.00 pp |
| Q1 2017 | 2017-03-31 | −39.34% | +2247.18 pp |
| Q4 2016 | 2016-12-31 | −152.49% | +3583.01 pp |
| Q3 2016 | 2016-09-30 | −1,666.26% | +70621.74 pp |
| Q2 2016 | 2016-06-30 | −678.74% | +1735.46 pp |
| Q1 2016 | 2016-03-31 | −2,286.52% | — |
| Q4 2015 | 2015-12-31 | −3,735.50% | — |
| Q3 2015 | 2015-09-30 | −72,288.00% | — |
| Q1 2015 | 2015-03-31 | −2,414.20% | — |
Over the last five reported fiscal years, Fortress Biotech's operating margin increased from −211.70% to −114.67%, a change of +97.03 percentage points. The latest reported quarter, Q2 2026, shows −56.09%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fortress Biotech filings at SEC.gov ↗